As more jurisdictions contemplate and pass laws to legalise cannabis for medical and non-medical purposes, the discussions about cannabis policy will likely become more intense in the EU. Member States can learn from these experiences and decide if they want to maintain their current cannabis supply policies or try something else. Those considering alternatives should remember that change need not be permanent; however, if profit-maximizing firms are allowed to produce and sell cannabis, they will have strong incentives to fight against regulations and policy changes that will negatively affect their bottom lines.
PDF files are made available as a convenience. In cases where the EMCDDA is not the originator of the document, please be aware that any PDFs available on this page may not be authoratative or there may be more recent versions available. While we make every effort to ensure that these files are definitive, before using or citing them, we recommend that you consult the publisher's website or contact the author(s) to check for more recent versions.
This paper was commissioned by the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) to provide background information to inform and contribute to the drafting of Health and social responses to drug problems: a European guide.
This background paper was produced under contract CT.16.SDI.0133.1.0 and we are grateful for the valuable contribution of the author. The paper has been cited within Health and social responses to drug problems and is also being made available online for those who would like further information on the topic. However, the views, interpretations and conclusions set out in this publication are those of the author and are not necessarily those of the EMCDDA or its partners, any EU Member State or any agency or institution of the European Union.